A multicentre randomized controlled clinical trial on amoxicillin/sulbactam in the treatment of acute bacterial infections

Objective To evaluate the efficacy and safety of amoxicillin/sulbactam (AMX/SBT) in the treatment of acute bacterial infections.Method A multicentre randomized controlled clinical trial was conducted.Ampicillin/sulbactam (AMP/ SBT) was chosen as the control drug. 113 patients were enrolled in the study (58 cases in test group and 55 cases in control group) .AMX/SUL and AMP/SUL were administered 4.5-6.0g and 4.5- 12.0g every day respectively.Both drugs were given intravenously for 7- 14 days. Results The cure rates and the efficacy rates of the two groups were 75.86% , 80.0% and 94.83 % , 98.18 % respectively. The β - lactamase producing rates were 67.35 % , 69.57 % and the bacterial clearance rates were 93.88 % , 95 .65 % . There were no significant differences of the above results between the two groups ( P 0.05) .There was no serious adverse drug reaction in AMX/SBT groups.Conclusion This study suggests that AMX/SBT is an effective and safe drug for treating acute bacterial infections.